Table 1.
Study subject demographics.
| Demographic characteristic | Group 1 |
Group 2 |
||||
|---|---|---|---|---|---|---|
| UX first-line therapy (n = 11) | UX second-line or above therapy (n = 32) | P-value | UX first-line therapy (n = 11) | NP first-line therapy (n = 60) | P-value | |
| Age (year), % | ||||||
| ≤50 | 6(54.55 %) | 17(53.13 %) | 0.935 | 6(54.55 %) | 36(60.00 %) | 0.735 |
| >50 | 5(45.45 %) | 15(46.87 %) | 5(45.45 %) | 24(40.00 %) | ||
| Menopause, % | ||||||
| Yes | 5(45.45 %) | 18(56.25 %) | 0.536 | 5(45.45 %) | 26(43.33 %) | >0.999 |
| No | 6(54.55 %) | 14(43.75 %) | 6(54.55 %) | 34(56.67 %) | ||
| BMI (kg/m2),% | ||||||
| ≤22 | 6(54.55 %) | 19(59.38 %) | 0.779 | 6(54.55 %) | 16(26.67 %) | 0.084 |
| >22 | 5(45.45 %) | 13(40.62 %) | 5(45.45 %) | 44(73.33 %) | ||
| T, % | ||||||
| ≤2 | 1(9.09 %) | 7(21.87 %) | 0.656 | 1(9.09 %) | 20(33.33 %) | 0.156 |
| >2 | 10(90.91 %) | 25(78.13 %) | 10(90.91 %) | 40(66.67 %) | ||
| N, % | ||||||
| Yes | 6(54.55 %) | 19(59.38 %) | 0.779 | 6(54.55 %) | 44(73.33 %) | 0.209 |
| No | 5(45.45 %) | 13(40.62 %) | 5(45.45 %) | 16(26.67 %) | ||
| M, % | ||||||
| No | 7(63.64 %) | 21(65.62 %) | 0.905 | 7(63.64 %) | 57(95.00 %) | 0.001 |
| Yes | 4(36.36 %) | 11(34.38 %) | 4(36.36 %) | 3(5.00 %) | ||
| ER, % | ||||||
| + | 6(54.55 %) | 14(43.75 %) | 0.536 | 6(54.55 %) | 40(66.67 %) | 0.439 |
| − | 5(45.45 %) | 18(56.25 %) | 5(45.45 %) | 20(33.33 %) | ||
| PR, % | ||||||
| + | 7(63.64 %) | 13(40.62 %) | 0.187 | 7(63.64 %) | 38(63.33 %) | 0.985 |
| − | 4(36.36 %) | 19(59.38 %) | 4(36.36 %) | 22(36.67 %) | ||
| HER2, % | ||||||
| + | 1(9.09 %) | 12(37.50 %) | 0.129 | 1(9.09 %) | 17(28.33 %) | 0.269 |
| − | 10(90.91 %) | 20(62.50 %) | 10(90.91 %) | 43(71.67 %) | ||
| Ki67, % | ||||||
| <14 | 1(9.09 %) | 6(18.75 %) | 0.656 | 1(9.09 %) | 11(18.33 %) | 0.676 |
| ≥14 | 10(90.91 %) | 26(81.25 %) | 10(90.91 %) | 49(81.67 %) | ||
| Metastasis site, % | ||||||
| ≤2 | 8(72.73 %) | 13(40.62 %) | 0.066 | 8(72.73 %) | 47(78.33 %) | 0.682 |
| >2 | 3(27.27 %) | 19(59.38 %) | 3(27.27 %) | 13(21.67 %) | ||
| Primary tumor excised, % | ||||||
| Yes | 8(72.73 %) | 23(71.88 %) | 0.957 | 8(72.73 %) | 56(93.33 %) | 0.035 |
| No | 3(27.27 %) | 9(28.12 %) | 3(27.27 %) | 4(6.67 %) | ||
| Received radiation therapy, % | ||||||
| Yes | 6(54.55 %) | 14(43.75 %) | 0.536 | 6(54.55 %) | 27(45.00 %) | 0.560 |
| No | 5(45.45 %) | 18(56.25 %) | 5(45.45 %) | 33(55.00 %) | ||
| Received targeted therapy, % | ||||||
| Yes | 3(27.27 %) | 11(34.38 %) | >0.999 | 3(27.27 %) | 10(16.67 %) | 0.411 |
| No | 8(72.73 %) | 21(65.62 %) | 8(72.73 %) | 50(83.33 %) | ||
| Received endocrine therapy, % | ||||||
| Yes | 4(36.36 %) | 11(34.38 %) | >0.999 | 4(36.36 %) | 24(40.00 %) | >0.999 |
| No | 7(63.64 %) | 21(65.62 %) | 7(63.64 %) | 36(60.00 %) | ||
BMI, body mass index; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor type 2; UX (Utidelone plus Capecitabine); NP (Vinorelbine plus Cisplatin).
ER and PR status was defined with the cutoff value of 1 % positive tumor cells.
HER2-positive was defined as scored 3+ by immunohistochemistry; for scores 2+, fluorescence in situ hybridization was performed to determine HER2 positivity; and 0 and 1+ were regarded as HER2-negative.